Back to Search Start Over

Adalimumab as a cause of kidney injury in patients with Crohn's disease.

Authors :
Skoczyński K
Koziej J
Szymańska S
Obrycki Ł
Grenda R
Litwin M
Source :
Pediatric nephrology (Berlin, Germany) [Pediatr Nephrol] 2024 Aug; Vol. 39 (8), pp. 2359-2361. Date of Electronic Publication: 2024 Mar 08.
Publication Year :
2024

Abstract

Introduction: Adalimumab (ADM) is a recombinant human monoclonal antibody (anti-TNFα) used to treat inflammatory bowel diseases. It can cause kidney injury (KI).<br />Case Diagnosis/treatment: We describe two pediatric patients with Crohn's disease (CD) in whom ADM therapy was associated with kidney injury (KI). The drug was discontinued in both cases. For the first patient, changes were irreversible despite intensive glucocorticosteroid (GCS) therapy. For the second patient, discontinuation of ADM led to an improvement in kidney function.<br />Conclusions: Due to the risk of KI in patients undergoing ADM therapy, careful assessment of kidney function and early specialist referral are required. Timely withdrawal of ADM can significantly reduce kidney damage, but in some cases, the kidney damage can be irreversible.<br /> (© 2024. The Author(s), under exclusive licence to International Pediatric Nephrology Association.)

Details

Language :
English
ISSN :
1432-198X
Volume :
39
Issue :
8
Database :
MEDLINE
Journal :
Pediatric nephrology (Berlin, Germany)
Publication Type :
Academic Journal
Accession number :
38456916
Full Text :
https://doi.org/10.1007/s00467-024-06338-0